CAS 1639792-20-3

Saroglitazar magnesium

Description:

Saroglitazar magnesium is a synthetic compound primarily used in the treatment of metabolic disorders, particularly for managing diabetes and dyslipidemia. It functions as a dual PPAR (peroxisome proliferator-activated receptor) agonist, specifically targeting PPAR-alpha and PPAR-gamma, which play crucial roles in lipid metabolism and glucose homeostasis. This compound is characterized by its ability to improve insulin sensitivity and reduce triglyceride levels, making it beneficial for patients with insulin resistance. Saroglitazar magnesium is typically administered in a specific dosage form, and its pharmacokinetics involve absorption, distribution, metabolism, and excretion processes that are essential for its therapeutic efficacy. Additionally, it has been studied for its potential effects on various metabolic parameters, contributing to its profile as a promising agent in the management of metabolic syndrome. As with any pharmaceutical, understanding its safety profile, potential side effects, and interactions with other medications is crucial for effective clinical use.

Synonyms:

• magnesium (S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate

Saroglitazar Magnesium

CAS: 1639792-20-3

Formula: C₅₀H₅₆MgN₂O₈S₂

Purity: 99%

Molecular weight: 901.4232

Ref: IN-DA01EOPB

Saroglitazar Magnesium

CAS: 1639792-20-3

Saroglitazar Magnesium: a PPAR agonist, strong on PPARα (EC50 0.65pM), moderate on PPARγ (EC50 3nM).

Formula: C₅₀H₅₆MgN₂O₈S₂

Purity: 98.1%

Color and Shape: Solid

Molecular weight: 901.43

Ref: TM-T12834

Saroglitazar Magnesium

CAS: 1639792-20-3

Saroglitazar Magnesium

Purity: ≥98%

Molecular weight: 901.43g/mol

Ref: 54-BUP15254

Saroglitazar Magnesium

CAS: 1639792-20-3

Formula: C₂₅H₂₉NO₄SMg

Molecular weight: 439.57 1/2*24.31

Ref: 4Z-S-267002

Saroglitazar magnesium

CAS: 1639792-20-3

Saroglitazar magnesium is a drug that belongs to the class of glp-1r agonists. It has been shown to improve insulin sensitivity and glucose tolerance in diabetic patients. Saroglitazar magnesium also has an effect on energy metabolism. It has been shown to increase the rate of fatty acid oxidation in rat liver microsomes and inhibit hepatic gluconeogenesis in vitro. Saroglitazar magnesium also has clinical relevance for metabolic disorders, polycystic ovarian syndrome, cirrhosis, and growth factor deficiency. Saroglitazar magnesium may be used as a statin adjunct for the treatment of high cholesterol or lipid levels, or as a pharmaceutical dosage for diabetes mellitus type 2 patients with cardiovascular diseases or renal impairment.

Formula: C₅₀H₅₆MgN₂O₈S₂

Purity: Min. 95%

Molecular weight: 901.4 g/mol

Ref: 3D-PQC79220